Global Malaria News
A recent study led by an entomologist explores the different kinds of cells that make up mosquito immune systems. The research could shed light on how mosquitoes transmit malaria.
A gene called PfAP2-HS allows the malaria parasite to defend itself from adverse conditions in the host, including febrile temperatures, according to new research. The study resolves a long-standing question on how the parasite responds to changes in its environment.
One dose of a new monoclonal antibody prevented malaria for up to nine months in people who were exposed to the malaria parasite. The small, carefully monitored clinical trial is the first to demonstrate that a monoclonal antibody can prevent malaria in people.
Researchers have shown 'gene drive' technology, which spreads a genetic modification blocking female reproduction, works in natural-like settings.
Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.
Infection with dengue virus makes mosquitoes more sensitive to warmer temperatures, according to new research. The team also found that infection with the bacterium Wolbachia, which has recently been used to control viral infections in mosquitoes, also increases the thermal sensitivity of the insects. The findings suggest that global warming could limit the spread of dengue fever but could also limit the effectiveness of Wolbachia as a biological control agent.
The parasites that cause severe malaria are well-known for the sinister ways they infect humans, but new research may lead to drugs that could block one of their most reliable weapons: interference with the immune response.
An estimated 8.4 billion people could be at risk from malaria and dengue by the end of the century if emissions keep rising at current levels, according to a new study.
Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs -- an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.
Six antibody characteristics could help scientists identify which pregnant women are at risk of placental malaria infections.
Scientists developed an mRNA vaccine that protects against malaria in animal models. Malaria remains a large public health and economic burden worldwide as well as a danger to deployed Service Members. This vaccine uses mRNA accompanied by a lipid nanoparticle to prompt cells to code for circumsporozoite protein, which then triggers an immune response against malaria. The vaccine achieved high levels of protection in mice, encouraging further development for the novel platform.
A faster method for collecting pure malaria parasites from infected mosquitos could accelerate the development of new, more potent malaria vaccines.
The role of people infected with malaria without showing symptoms presents a hidden risk to efforts to control the disease after they were found to be responsible for most infections in mosquitoes, according to a new study.
Artemisone is a promising substance in the fight against malaria. However, the active ingredient has yet to be used due its instability and because it is not easily absorbed by the body. A team has now pushed this a bit further. They have developed a very simple method for preparing the active ingredient that makes it easier to administer and store.
Malaria, a disease caused mainly by the parasites Plasmodium falciparum and Plasmodium vivax, is associated with over 400,000 deaths each year. Previously, the spleen was assumed to mostly play a role in parasite destruction, as it eliminates malaria parasites after antimalarial treatment. A new study suggests that in chronic P. vivax infections, malaria parasites survive and replicate via a previously undetected lifecycle within the spleen.
Scientists have developed a genetics toolkit that helps pave the way to a gene drive designed to stop Culex mosquitoes from spreading disease. Much less studied than other genera, Culex mosquitoes spread devastating afflictions stemming from West Nile virus, Japanese encephalitis virus and the pathogen causing avian malaria.
Climate change will make outbreaks of West Nile virus more likely in the UK within the next 20-30 years, a new study has found. A new scientific model shows the risk of the mosquito-borne pathogen spreading to the country will increase as temperatures rise.
Researchers have designed a drug-like compound which effectively blocks a critical step in the malaria parasite life cycle and are working to develop this compound into a potential first of its kind malaria treatment.
Researchers have identified how natural human antibodies can block malaria parasites from entering red blood cells, potentially indicating how new protective therapies could be developed against this globally significant disease. The research provides greater insight into how antibodies block the entry of Plasmodium vivax malaria parasites into young red blood cells called reticulocytes. It builds on an earlier discovery that the P. vivax latches onto the transferrin receptor 1 (TfR1) to enter cells.
Researchers reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77 percent over 12 months of follow-up.